P. Jakobs

A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial of Deferasirox (Exjade®) in Patients with Low/Intermediate-1 Risk MDS and Transfusional Iron Overload.

G. Garcia-Manero, E. Angelucci, D. Bowen, 2009 .

Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes

H P Hartung, F Barkhof, C H Polman, 2006, Neurology.

P129 Severe iron overload in patients with myelodysplastic syndromes (MDS) enrolled in a large study of deferasirox (Exjade®, ICL670)

C. Finelli, M. Schmid, C. Rose, 2007 .

Oral interferon beta-1a in relapsing-remitting multiple sclerosis: a double-blind randomized study

F. Barkhof, C. Pozzilli, L. Kappos, 2003, Multiple sclerosis.

Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.

R. Mandler, S. Lynch, D. Jeffery, 2008, Clinical therapeutics.

Blockade of chemokine signaling in patients with multiple sclerosis

M. Filippi, H. Hartung, F. Zipp, 2006, Neurology.

Tolerability and safety profile of 12- to 28-week treatment with interferon beta-1b 250 and 500 microg QOD in patients with relapsing-remitting multiple sclerosis: a multicenter, randomized, double-blind, parallel-group pilot study.

R. Mandler, S. Lynch, D. Jeffery, 2008, Clinical therapeutics.